Lucatumumab

Drug Profile

Lucatumumab

Alternative Names: CHIR-12.12; HCD-122

Latest Information Update: 10 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Novartis; XOMA
  • Class Antineoplastics; Monoclonal antibodies
  • Mechanism of Action CD40 antigen inhibitors; Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Chronic lymphocytic leukaemia; Follicular lymphoma; Lymphoma; Multiple myeloma

Most Recent Events

  • 15 Dec 2016 Biomarkers information updated
  • 23 Jan 2013 Discontinued - Phase-I for Follicular lymphoma (combination therapy, second-line therapy or greater) in Belgium (IV)
  • 23 Jan 2013 Discontinued - Phase-I for Follicular lymphoma (combination therapy, second-line therapy or greater) in USA (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top